Context Therapeutics Inc. (NASDAQ:CNTX) Given Consensus Rating of “Buy” by Analysts

Shares of Context Therapeutics Inc. (NASDAQ:CNTX) have earned a consensus rating of “Buy” from the seven brokerages that are covering the stock, MarketBeat.com reports. Six research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 1-year price objective among brokers that have updated their coverage on the stock in the last year is $6.33.

Several research firms have commented on CNTX. Citizens Jmp upgraded shares of Context Therapeutics to a “strong-buy” rating in a research report on Wednesday, January 8th. D. Boral Capital started coverage on shares of Context Therapeutics in a report on Monday, November 25th. They issued a “buy” rating and a $9.00 price target for the company. JMP Securities started coverage on Context Therapeutics in a research report on Wednesday, January 8th. They issued an “outperform” rating and a $4.00 price target for the company. Finally, HC Wainwright restated a “buy” rating and set a $6.00 price objective on shares of Context Therapeutics in a research report on Monday, September 23rd.

Institutional Trading of Context Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Driehaus Capital Management LLC bought a new position in shares of Context Therapeutics during the second quarter valued at approximately $4,527,000. Great Point Partners LLC purchased a new position in Context Therapeutics during the 2nd quarter valued at $14,876,000. Blue Owl Capital Holdings LP purchased a new position in Context Therapeutics during the 2nd quarter valued at $10,348,000. State Street Corp grew its position in Context Therapeutics by 21.5% in the 3rd quarter. State Street Corp now owns 111,907 shares of the company’s stock valued at $219,000 after acquiring an additional 19,800 shares during the last quarter. Finally, Nantahala Capital Management LLC purchased a new stake in Context Therapeutics in the second quarter worth $3,881,000. 14.03% of the stock is owned by hedge funds and other institutional investors.

Context Therapeutics Price Performance

NASDAQ CNTX opened at $1.08 on Wednesday. Context Therapeutics has a 1-year low of $0.89 and a 1-year high of $2.75. The business has a 50 day simple moving average of $1.47 and a two-hundred day simple moving average of $1.92. The stock has a market capitalization of $81.00 million, a PE ratio of -1.19 and a beta of 2.10.

Context Therapeutics (NASDAQ:CNTX) last posted its earnings results on Wednesday, November 6th. The company reported ($0.22) EPS for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.11). On average, analysts anticipate that Context Therapeutics will post -0.51 EPS for the current fiscal year.

Context Therapeutics Company Profile

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.